Datasets:
chrisvoncsefalvay
/
vaers-narrative-generation

Dataset card Data Studio Files
xet
Community
1
instruction
stringclasses
1 value
input
stringlengths
19
390
output
stringlengths
1
32k
Generate a clinical symptom description based on the patient and vaccine information provided
Vaccine: VARZOS Symptoms: Herpes zoster, Ophthalmic herpes zoster, Vaccination failure, Zoster sine herpete
Suspected vaccination failure; had it on my eye and 30 days from that, internal, and then on my head; Internal shingles; Shingles on head; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant), ophthalmic herpes zoster (Verbatim: had it on my eye and 30 days from that, internal, and then on my head) (serious criteria GSK medically significant), zoster sine herpete (Verbatim: Internal shingles) and shingles (Verbatim: Shingles on head). The outcome of the vaccination failure, ophthalmic herpes zoster, zoster sine herpete and shingles were not reported. The reporter considered the vaccination failure, ophthalmic herpes zoster, zoster sine herpete and shingles to be possibly related to Shingles vaccine. The company considered the vaccination failure and ophthalmic herpes zoster to be unrelated to Shingles vaccine. The company considered the zoster sine herpete and shingles to be possibly related to Shingles vaccine. Additional Information: GSK Receipt Date: 20-AUG-2025 This case was reported by a patient via interactive digital media. The reporter reported that same had it on eye and 30 days from that, internal, and then on head. The reporter was also mentioned that the vaccination be triggered it. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of disease) is considered unrelated to GSK Shingles vaccine. A case of Ophthalmic herpes zoster, unknown time after receiving Shingles vaccine in a patient. Report is inconsistent with causal relation to the vaccine product, considering absence of biological plausibility.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 21.0 Sex: F Vaccine: COVID19, HPV9, TTOX Symptoms: Fatigue, Headache, Hypertension, Mast cell activation syndrome, Photophobia
She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic; high blood pressure; sensitivity to light; headaches; fatigue; rashes; This spontaneous case was reported by a consumer and describes the occurrence of MAST CELL ACTIVATION SYNDROME (She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic) in a 21-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. Co-suspect products included non-company products HPV vaccine VLP rL1 9v (yeast) (Gardasil 9) for HPV vaccine and Tetanus vaccine toxoid (Tetanus vaccine) for an unknown indication. The patient's past medical history included Raynaud's disease (Two different times, once in middle school and once in high school, the patient was diagnosed with Raynaud's Disease. Fingers were painful, difficulty opening bottles. Some days were better than others, but no comparison to how she was prior to receiving the three shots). On 13-May-2024, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form, dose of HPV vaccine VLP rL1 9v (yeast) (Gardasil 9) (unknown route) 1 dosage form and dose of Tetanus vaccine toxoid (Tetanus vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MAST CELL ACTIVATION SYNDROME (She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic) (seriousness criterion medically significant), HYPERTENSION (high blood pressure), PHOTOPHOBIA (sensitivity to light), HEADACHE (headaches), FATIGUE (fatigue) and RASH (rashes). At the time of the report, MAST CELL ACTIVATION SYNDROME (She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic), HYPERTENSION (high blood pressure), PHOTOPHOBIA (sensitivity to light), HEADACHE (headaches), FATIGUE (fatigue) and RASH (rashes) outcome was unknown. The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown. For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments. Concomitant medication was not reported. Patient did not have any known allergies. The patient had adverse effect impacts for more than a year due to taking Gardasil 9. She received the Gardasil 9 vaccine, a Moderna vaccine shot and a Tetanus shot. Ever since receiving the shots, she had been a shell of herself. The patient was in bed from 15-May-2024 through all last summer. She went to her senior year of college in the fall of 2024. During the year, the patient missed a lot of classes and needed a lot of rest. She had been to numerous doctors at the clinic while in college. The patient wanted to know if it was safe to administer the Gardasil 9 along with the Covid and Tetanus shots, and asked about how to know for sure that which vaccine was causing the issues. She was trying to find out which vaccine had caused the issues. Patient had undergone bloodwork, ziopatch test for heart monitoring and Gold Standard Potts Diagnosis tests and results were not reported. Treatment medication was not reported.; Reporter's Comments: Co-suspect products HPV vaccine VLP rL1 9v, Tetanus vaccine and past medical history of Raynaud's disease are confounders for the events. The benefit -risk relationship of product is not affected by this report.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 21.0 Sex: F Vaccine: COVID19, HPV9, TTOX Symptoms: Rash
She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic; high blood pressure; sensitivity to light; headaches; fatigue; rashes; This spontaneous case was reported by a consumer and describes the occurrence of MAST CELL ACTIVATION SYNDROME (She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic) in a 21-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. Co-suspect products included non-company products HPV vaccine VLP rL1 9v (yeast) (Gardasil 9) for HPV vaccine and Tetanus vaccine toxoid (Tetanus vaccine) for an unknown indication. The patient's past medical history included Raynaud's disease (Two different times, once in middle school and once in high school, the patient was diagnosed with Raynaud's Disease. Fingers were painful, difficulty opening bottles. Some days were better than others, but no comparison to how she was prior to receiving the three shots). On 13-May-2024, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form, dose of HPV vaccine VLP rL1 9v (yeast) (Gardasil 9) (unknown route) 1 dosage form and dose of Tetanus vaccine toxoid (Tetanus vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MAST CELL ACTIVATION SYNDROME (She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic) (seriousness criterion medically significant), HYPERTENSION (high blood pressure), PHOTOPHOBIA (sensitivity to light), HEADACHE (headaches), FATIGUE (fatigue) and RASH (rashes). At the time of the report, MAST CELL ACTIVATION SYNDROME (She now has MCAS - Mast Cell Activation Syndrome by an allergy clinic), HYPERTENSION (high blood pressure), PHOTOPHOBIA (sensitivity to light), HEADACHE (headaches), FATIGUE (fatigue) and RASH (rashes) outcome was unknown. The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown. For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments. Concomitant medication was not reported. Patient did not have any known allergies. The patient had adverse effect impacts for more than a year due to taking Gardasil 9. She received the Gardasil 9 vaccine, a Moderna vaccine shot and a Tetanus shot. Ever since receiving the shots, she had been a shell of herself. The patient was in bed from 15-May-2024 through all last summer. She went to her senior year of college in the fall of 2024. During the year, the patient missed a lot of classes and needed a lot of rest. She had been to numerous doctors at the clinic while in college. The patient wanted to know if it was safe to administer the Gardasil 9 along with the Covid and Tetanus shots, and asked about how to know for sure that which vaccine was causing the issues. She was trying to find out which vaccine had caused the issues. Patient had undergone bloodwork, ziopatch test for heart monitoring and Gold Standard Potts Diagnosis tests and results were not reported. Treatment medication was not reported.; Reporter's Comments: Co-suspect products HPV vaccine VLP rL1 9v, Tetanus vaccine and past medical history of Raynaud's disease are confounders for the events. The benefit -risk relationship of product is not affected by this report.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 69.0 Sex: F Vaccine: COVID19 Symptoms: Arthralgia, COVID-19, Triple negative breast cancer
she also got COVID around 6 months after her breast cancer surgery; after each COVID vaccine her shins and joints ache for 8-10 hours; fast growing triple negative breast cancer (40%); This spontaneous case was reported by a consumer and describes the occurrence of TRIPLE NEGATIVE BREAST CANCER (fast growing triple negative breast cancer (40%)) and COVID-19 (she also got COVID around 6 months after her breast cancer surgery) in an elderly female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (batch nos. 3031894 and 204H23-2A) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Lupus syndrome (Lupus). On 14-Oct-2023, the patient received seventh dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (unknown route) 1 dosage form. On 28-Jul-2024, received eighth dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (unknown route) dosage was changed to 1 dosage form. In July 2024, the patient experienced TRIPLE NEGATIVE BREAST CANCER (fast growing triple negative breast cancer (40%)) (seriousness criterion medically significant). On an unknown date, the patient experienced COVID-19 (she also got COVID around 6 months after her breast cancer surgery) (seriousness criterion medically significant) and ARTHRALGIA (after each COVID vaccine her shins and joints ache for 8-10 hours). At the time of the report, TRIPLE NEGATIVE BREAST CANCER (fast growing triple negative breast cancer (40%)) and COVID-19 (she also got COVID around 6 months after her breast cancer surgery) outcome was unknown and ARTHRALGIA (after each COVID vaccine her shins and joints ache for 8-10 hours) had resolved. No concomitant medication was reported. The patient was diagnosed with fast growing triple negative breast cancer (40%) in Jul-2024. It took one year and a half to become large enough to find and they found it early. They started chemo two weeks after they found it. She reported that triple negative was the deadliest form of breast cancer, so her team jumped on it and did a really good job. Over the past year she had been done with 2 rounds of chemotherapy and a full round of radiation and reported that she did not have an immune system. She was told by her cancer specialist to hurry, and she got a COVID shot for her immune system. She also got COVID around 6 months after her breast cancer surgery. Her breast cancer surgery was in Jul-2024. She reported that she was sick, but Moderna saved her life. If she hadn't had that vaccine, even if she would have Pfizer, the percentage was much lower. She blamed Moderna for saving her life. She reported that that after each COVID vaccine her shins and joints ache for 8-10 hours. She thought it was just her body trying to make antibodies. She was 3 months out of radiation and did not have her first check-up. It was unknown if the patient experienced any additional symptoms/events. This case was linked to MOD-2025-788868, MOD-2025-788869 (Patient Link).; Reporter's Comments: Concurrent medical condition Lupus syndrome is a confounder for arthralgia event. Due to lack of biological plausibility, the causality of the event Triple negative breast cancer was assessed as not related to the vaccine. The benefit -risk relationship of product is not affected by this report.
Generate a clinical symptom description based on the patient and vaccine information provided
Sex: F Vaccine: COVID19 Symptoms: COVID-19, Drug ineffective
really hurting too. There's this like stabbing in my throat feeling and I've had it before, I've used Paxlovid before; really hurting too. There's this like stabbing in my throat feeling and I've had it before, I've used Paxlovid before; This is a spontaneous report received from a Consumer or other non HCP, Program ID:. A 58-year-old female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), in Sep2024 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete), for COVID-19 immunization; Bnt162b2 (dose number unknown (booster)), for COVID-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "really hurting too. There's this like stabbing in my throat feeling and I've had it before, I've used Paxlovid before". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: The patient stated, "(inaudible) really hurting too. There's this like stabbing in my throat feeling and I've had it before, I've used Paxlovid before. I've gotten the booster every year." Later while searching for the patients account she added, "I have my Pfizer booster every year I wasn't due for it yet, I had it in at the end of Sep of last year (2024) so obviously (inaudible)." The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 84.0 Sex: M Vaccine: COVID19 Symptoms: COVID-19, Drug ineffective
came down with the COVID/still picked up this variant; came down with the COVID/still picked up this variant; This is a spontaneous report and received from Consumer or other non HCPs, Program ID:. An 84-year-old male patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), in Jun2025 as dose 1, single (Batch/Lot number: unknown) at the age of 84 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Primary Immunization series complete), for COVID-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2025, outcome "unknown" and all described as "came down with the COVID/still picked up this variant". Clinical course: During an inbound call for financial assistance, the patient, (name withheld), stated, "I wish I had applied for my Part D at the start, but I'm 84, I'm not sure I can get it." When (name withheld) was asked if he had any further questions, an unknown person, who joined the call, stated, "I have a question. When I came down, I came down with the COVID first, and (name withheld) came down a day later. But I applied and I got-I got the pills for free, especially when you're sick and your brain doesn't work right anymore." After explaining the differences between the different programs offered, (name withheld) stated, "I think that-that you've helped us as much as you can, and it looks like we have to go through the government first and then go from there. But by that time, hopefully I will be over COVID." After explaining to (name withheld) that he is not eligible for the program initially, (name withheld) asked, "So, I do, or I don't?" The unknown person then answered, "You don't, but you're retired, so I don't know what they're going by because you just retired this year." Later in the call, the unknown person stated, "It's bad enough having COVID without being penalized, you know. And I must tell you that we have always kept our Pfizer vaccines up. We had our last one in Jun, but we still picked up this variant, whatever it is, and, anyway, they've always-the vaccines have always been very successful. My mother's 99, and she was living with us until a few months ago, so we were careful, but she's not with us now." At the end of the call, the unknown person stated, "Okay, I'm going to give this information to a neighbor since we have COVID and we're quarantined. So a neighbor be able to pick this up for us, I guess." The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Generate a clinical symptom description based on the patient and vaccine information provided
Sex: F Vaccine: COVID19 Symptoms: Cerebrovascular accident
stroke; This is a spontaneous report received from a Consumer or other non HCP. A female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "alzheimer" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Premarin, reaction(s): "Stroke". The following information was reported: CEREBROVASCULAR ACCIDENT (medically significant), outcome "unknown", described as "stroke". The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Generate a clinical symptom description based on the patient and vaccine information provided
Sex: F Vaccine: COVID19 Symptoms: Drug ineffective, Suspected COVID-19
there is a chance that I could have had covid, I had a kind of fluish period of time; there is a chance that I could have had covid, I had a kind of fluish period of time; This is a spontaneous report received from a Consumer or other non HCP from medical information team, Program ID. A 74-year-old female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), in Sep2024 as dose 1,single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "there is a chance that I could have had covid, I had a kind of fluish period of time". Clinical course: per caller she was thinking that she need another booster, and that they could give her a titer blood test to see if she still had immunity against a covid virus. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Generate a clinical symptom description based on the patient and vaccine information provided
Sex: M Vaccine: COVID19 Symptoms: Metastasis
metastasis of prostate cancer.; This is a spontaneous report received from a Physician from a sales representative. An elderly male patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Metastatic Prostate Cancer" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE; manufacturer unknown), for Covid-19 immunisation; Covid-19 vaccine (DOSE 2, SINGLE; manufacturer unknown), for Covid-19 immunisation. The following information was reported: METASTASIS (life threatening, medically significant), 1 month after the suspect product(s) administration, outcome "recovering", described as "metastasis of prostate cancer.". Therapeutic measures were taken as a result of metastasis. Clinical course: Dr. reported about a month after he received his 3rd Pfizer Covid vaccine, he had metastasis of prostate cancer. Dr. considered the event resulted in life threatening illness (immediate risk of death from the event). The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.; Sender's Comments: As there is limited information in the case provided, the causal association between the event metastasis and the suspect drug BNT162B2 OMICRON (KP.2) cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit-risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Generate a clinical symptom description based on the patient and vaccine information provided
Vaccine: COVID19 Symptoms: COVID-19, Drug ineffective
I came down with the COVID; I came down with the COVID; This is a spontaneous report and received from Consumer or other non HCPs, Program ID:. A patient (age and gender not provided) received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), in Jun2025 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Primary Immunization series complete), for COVID-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2025, outcome "unknown" and all described as "I came down with the COVID". Therapeutic measures were taken as a result of covid-19. The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 31.0 Sex: M Vaccine: COVID19, COVID19 Symptoms: Arthralgia, Blood test normal, Rheumatoid factor negative
Joint pain in hands that never fully went away. Within 1-2 weeks of the vaccine my hands suddenly felt like I was 80 years old, it gradually got better but it never went away. The same thing happened after boosters. It's been 4 1/2 years and hands still hurt.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 57.0 Sex: F Vaccine: COVID19 Symptoms: Arthralgia, Asthenia, Dysstasia, Fatigue, Hypoaesthesia
pt says she on 2/26/21 she was feeling very fatigue and she didn't have any leg strength. She was very weak. At work she had a sharp pain that went from her hip and went down her right leg. She immediately sat down. She had to called the ambulance because she couldn't stand up. She was taken to Hospital ER. She couldn't feel it when they lifted her right leg. She was admitted and was there for over 2 weeks. She was diagnosed with Transverse myelitis that affected both legs and lower part of her body. She is currently wheelchair bound and disabled. Had to go to (withheld name) rehab after being discharged. She is currently being treated by a neurologist Dr. at the MS clinic.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 57.0 Sex: F Vaccine: COVID19 Symptoms: Laboratory test, Magnetic resonance imaging, Muscular weakness, Myelitis transverse, Pain in extremity
pt says she on 2/26/21 she was feeling very fatigue and she didn't have any leg strength. She was very weak. At work she had a sharp pain that went from her hip and went down her right leg. She immediately sat down. She had to called the ambulance because she couldn't stand up. She was taken to Hospital ER. She couldn't feel it when they lifted her right leg. She was admitted and was there for over 2 weeks. She was diagnosed with Transverse myelitis that affected both legs and lower part of her body. She is currently wheelchair bound and disabled. Had to go to (withheld name) rehab after being discharged. She is currently being treated by a neurologist Dr. at the MS clinic.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 57.0 Sex: F Vaccine: COVID19 Symptoms: Plasmapheresis, Wheelchair user
pt says she on 2/26/21 she was feeling very fatigue and she didn't have any leg strength. She was very weak. At work she had a sharp pain that went from her hip and went down her right leg. She immediately sat down. She had to called the ambulance because she couldn't stand up. She was taken to Hospital ER. She couldn't feel it when they lifted her right leg. She was admitted and was there for over 2 weeks. She was diagnosed with Transverse myelitis that affected both legs and lower part of her body. She is currently wheelchair bound and disabled. Had to go to (withheld name) rehab after being discharged. She is currently being treated by a neurologist Dr. at the MS clinic.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 66.0 Sex: F Vaccine: FLU3 Symptoms: Dizziness, Fatigue, Feeling cold, Muscular weakness, Pyrexia
I got the injection around noon, and i came home and i sat down with my dog and a cup of coffee and then all of the sudden i was freezing and i couldn't get warm. Then i got tired, fever, throwing up, dizzy. My legs are very weak.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 66.0 Sex: F Vaccine: FLU3 Symptoms: Vomiting
I got the injection around noon, and i came home and i sat down with my dog and a cup of coffee and then all of the sudden i was freezing and i couldn't get warm. Then i got tired, fever, throwing up, dizzy. My legs are very weak.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 32.0 Sex: M Vaccine: COVID19 Symptoms: Antinuclear antibody negative, Biopsy peripheral nerve, Blood pressure fluctuation, Borrelia test negative, Brain fog
Arm, wrist, leg swelling that comes and goes and has persisted to this day. Brain fog, very sensitive to noise. very fatigued. Occasional tremors. Fluctation in blood pressure, POTS
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 32.0 Sex: M Vaccine: COVID19 Symptoms: Chest X-ray normal, Computerised tomogram head normal, Fatigue, Hyperacusis, Joint swelling
Arm, wrist, leg swelling that comes and goes and has persisted to this day. Brain fog, very sensitive to noise. very fatigued. Occasional tremors. Fluctation in blood pressure, POTS
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 32.0 Sex: M Vaccine: COVID19 Symptoms: Peripheral swelling, Postural orthostatic tachycardia syndrome, SARS-CoV-2 antibody test positive, Tremor
Arm, wrist, leg swelling that comes and goes and has persisted to this day. Brain fog, very sensitive to noise. very fatigued. Occasional tremors. Fluctation in blood pressure, POTS
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 45.0 Sex: F Vaccine: HPV4, HPV4, HPV4 Symptoms: Androgenetic alopecia, Dysphonia, Formication, Hair texture abnormal, Inflammation
alopecia/bald spot/autoimmune injury/hair loss; extreme and unusual pain in her arm; swollen face and neck; swollen face and neck; eyes receded into her face; voice changed; felt as if something is crawling in her hair/itchiness on her scalp; he texture of her hair completely changed; inflammation; occasional pain in her scalp; Information has been received from a lawyer referring to a 45-year-old female patient regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. On an unknown date, at 45 years old, the patient received 3 doses of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (strength, dose, route, lot#, and expiration date were not reported). The patient agreed to receive the vaccine after being convinced that the vaccine was very safe, that the vaccine prevented cancer. The patient relied upon the company's ubiquitous representations concerning the safety and efficacy of the vaccine, in consenting to her vaccination. The patient's health care provider recommended that she receive the Gardasil vaccine, which was touted as a safe and effective vaccine for preventing cervical cancer. Upon information and belief, the patient's doctor read and relied upon information from the company, through its labeling and/or marketing, that the vaccine was safe and effective. In light of the patient's doctor's recommendations, as well as the company's relentless marketing and advertising messages, to which the patient had been exposed concerning the safety and efficacy of the vaccine, the patient consented to being injected with the vaccine. After receiving the second Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, the patient experienced extreme and unusual pain in her arm and called the office immediately. The nurse that administered the vaccine said that this Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine was a "rough shot" and advised she would experience pain for three weeks. The following day, the patient woke up to a swollen face and neck. The patient's eyes receded into her face and her voice changed from swelling in her neck. In between the second and third Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, the patient went to the emergency room three times for facial swelling. The doctors could not diagnose her, but she was prescribed water pills and blood pressure medication to decrease her swelling. The patient visited her primary care provider once a month for the swelling and still received no answers or diagnosis to these symptoms. The patient became ill within two days after receiving the last Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) shot. She developed a bald spot, and the texture of her hair completely changed. Thereafter, the patient visited a specialist and was diagnosed with alopecia. The patient had to cut off all her hair, purchased costly hair products, and over the counter supplements to counteract her hair loss and inflammation. She still suffered from occasional pain in her scalp and felt as if something is crawling in her hair. As the months progressed, so did the patient's symptoms. She was seen by multiple physicians and specialists for her complaints which now included: facial and neck swelling, hair loss, and pain and itchiness on her scalp. Following her vaccinations, the patient's confidence has been deeply shaken because of the physical changes she had experienced following her vaccinations. Based upon her chronic and severe post-Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) symptoms, the patient has been diagnosed with various medical conditions, including but not limited to, alopecia. The patient contended that her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections caused her to develop serious and debilitating autoimmune injuries, including but not limited to, alopecia, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which were alleged herein and all of which were caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) or otherwise linked to her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL)-induced autoimmune disorder. As a proximate result of company's wrongful acts and the vaccine's manufacturing defects, the patient has suffered and continued to suffer severe and permanent physical injuries and permanent emotional injuries, including pain and suffering. The patient also has a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of her vaccine-induced injuries, the patient had suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she will continue to incur these losses and expenses in the future. The outcome of the events was not recovered. The causality between the events and Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) was considered to be related. The lawyer considered the events to be disability.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 45.0 Sex: F Vaccine: HPV4, HPV4, HPV4 Symptoms: Lid sulcus deepened, Malaise, Pain in extremity, Pain of skin, Pruritus
alopecia/bald spot/autoimmune injury/hair loss; extreme and unusual pain in her arm; swollen face and neck; swollen face and neck; eyes receded into her face; voice changed; felt as if something is crawling in her hair/itchiness on her scalp; he texture of her hair completely changed; inflammation; occasional pain in her scalp; Information has been received from a lawyer referring to a 45-year-old female patient regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. On an unknown date, at 45 years old, the patient received 3 doses of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (strength, dose, route, lot#, and expiration date were not reported). The patient agreed to receive the vaccine after being convinced that the vaccine was very safe, that the vaccine prevented cancer. The patient relied upon the company's ubiquitous representations concerning the safety and efficacy of the vaccine, in consenting to her vaccination. The patient's health care provider recommended that she receive the Gardasil vaccine, which was touted as a safe and effective vaccine for preventing cervical cancer. Upon information and belief, the patient's doctor read and relied upon information from the company, through its labeling and/or marketing, that the vaccine was safe and effective. In light of the patient's doctor's recommendations, as well as the company's relentless marketing and advertising messages, to which the patient had been exposed concerning the safety and efficacy of the vaccine, the patient consented to being injected with the vaccine. After receiving the second Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, the patient experienced extreme and unusual pain in her arm and called the office immediately. The nurse that administered the vaccine said that this Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine was a "rough shot" and advised she would experience pain for three weeks. The following day, the patient woke up to a swollen face and neck. The patient's eyes receded into her face and her voice changed from swelling in her neck. In between the second and third Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, the patient went to the emergency room three times for facial swelling. The doctors could not diagnose her, but she was prescribed water pills and blood pressure medication to decrease her swelling. The patient visited her primary care provider once a month for the swelling and still received no answers or diagnosis to these symptoms. The patient became ill within two days after receiving the last Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) shot. She developed a bald spot, and the texture of her hair completely changed. Thereafter, the patient visited a specialist and was diagnosed with alopecia. The patient had to cut off all her hair, purchased costly hair products, and over the counter supplements to counteract her hair loss and inflammation. She still suffered from occasional pain in her scalp and felt as if something is crawling in her hair. As the months progressed, so did the patient's symptoms. She was seen by multiple physicians and specialists for her complaints which now included: facial and neck swelling, hair loss, and pain and itchiness on her scalp. Following her vaccinations, the patient's confidence has been deeply shaken because of the physical changes she had experienced following her vaccinations. Based upon her chronic and severe post-Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) symptoms, the patient has been diagnosed with various medical conditions, including but not limited to, alopecia. The patient contended that her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections caused her to develop serious and debilitating autoimmune injuries, including but not limited to, alopecia, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which were alleged herein and all of which were caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) or otherwise linked to her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL)-induced autoimmune disorder. As a proximate result of company's wrongful acts and the vaccine's manufacturing defects, the patient has suffered and continued to suffer severe and permanent physical injuries and permanent emotional injuries, including pain and suffering. The patient also has a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of her vaccine-induced injuries, the patient had suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she will continue to incur these losses and expenses in the future. The outcome of the events was not recovered. The causality between the events and Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) was considered to be related. The lawyer considered the events to be disability.
Generate a clinical symptom description based on the patient and vaccine information provided
Age: 45.0 Sex: F Vaccine: HPV4, HPV4, HPV4 Symptoms: Swelling, Swelling face
alopecia/bald spot/autoimmune injury/hair loss; extreme and unusual pain in her arm; swollen face and neck; swollen face and neck; eyes receded into her face; voice changed; felt as if something is crawling in her hair/itchiness on her scalp; he texture of her hair completely changed; inflammation; occasional pain in her scalp; Information has been received from a lawyer referring to a 45-year-old female patient regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. On an unknown date, at 45 years old, the patient received 3 doses of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (strength, dose, route, lot#, and expiration date were not reported). The patient agreed to receive the vaccine after being convinced that the vaccine was very safe, that the vaccine prevented cancer. The patient relied upon the company's ubiquitous representations concerning the safety and efficacy of the vaccine, in consenting to her vaccination. The patient's health care provider recommended that she receive the Gardasil vaccine, which was touted as a safe and effective vaccine for preventing cervical cancer. Upon information and belief, the patient's doctor read and relied upon information from the company, through its labeling and/or marketing, that the vaccine was safe and effective. In light of the patient's doctor's recommendations, as well as the company's relentless marketing and advertising messages, to which the patient had been exposed concerning the safety and efficacy of the vaccine, the patient consented to being injected with the vaccine. After receiving the second Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, the patient experienced extreme and unusual pain in her arm and called the office immediately. The nurse that administered the vaccine said that this Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine was a "rough shot" and advised she would experience pain for three weeks. The following day, the patient woke up to a swollen face and neck. The patient's eyes receded into her face and her voice changed from swelling in her neck. In between the second and third Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, the patient went to the emergency room three times for facial swelling. The doctors could not diagnose her, but she was prescribed water pills and blood pressure medication to decrease her swelling. The patient visited her primary care provider once a month for the swelling and still received no answers or diagnosis to these symptoms. The patient became ill within two days after receiving the last Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) shot. She developed a bald spot, and the texture of her hair completely changed. Thereafter, the patient visited a specialist and was diagnosed with alopecia. The patient had to cut off all her hair, purchased costly hair products, and over the counter supplements to counteract her hair loss and inflammation. She still suffered from occasional pain in her scalp and felt as if something is crawling in her hair. As the months progressed, so did the patient's symptoms. She was seen by multiple physicians and specialists for her complaints which now included: facial and neck swelling, hair loss, and pain and itchiness on her scalp. Following her vaccinations, the patient's confidence has been deeply shaken because of the physical changes she had experienced following her vaccinations. Based upon her chronic and severe post-Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) symptoms, the patient has been diagnosed with various medical conditions, including but not limited to, alopecia. The patient contended that her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections caused her to develop serious and debilitating autoimmune injuries, including but not limited to, alopecia, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which were alleged herein and all of which were caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) or otherwise linked to her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL)-induced autoimmune disorder. As a proximate result of company's wrongful acts and the vaccine's manufacturing defects, the patient has suffered and continued to suffer severe and permanent physical injuries and permanent emotional injuries, including pain and suffering. The patient also has a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of her vaccine-induced injuries, the patient had suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity, and she will continue to incur these losses and expenses in the future. The outcome of the events was not recovered. The causality between the events and Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) was considered to be related. The lawyer considered the events to be disability.